FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048606852> ?p ?o ?g. }

• W3048606852 endingPage "e036245" @default.
• W3048606852 startingPage "e036245" @default.
• W3048606852 abstract "Objectives The objectives of this study were to describe the demographic profile and baseline disease characteristics of patients with psoriatic arthritis (PsA) treated with either infliximab (IFX), subcutaneous golimumab (GLM) or ustekinumab (UST) treatment in Canadian routine care setting along with assessing long-term effectiveness and safety. Methods Patients with PsA were enrolled into the Biologic Treatment Registry Across Canada registry (ClinicalTrials.gov Identifier: NCT00741793 ) from 2005 to 2017. The study visits occurred at study enrolment (baseline) and every 6 months thereafter. Effectiveness was assessed by changes in disease parameters (joint counts, Psoriasis Area Severity Index (PASI), Health Assessment Questionnaire, patient/physician global, minimal disease activity, enthesitis, dactylitis, erythrocyte sedimentation rate, C reactive protein). Improvements from baseline were explored with the paired t-test and the McNemar’s test. Safety was evaluated by assessing the incidence of adverse events (AEs) and drug survival rates. Results A total of 111 IFX-treated, 281 GLM-treated and 70 UST-treated patients were enrolled. Most baseline disease parameters remained similar over time in all three cohorts. UST-treated patients had lower mean baseline Disease Activity Score in 28 joints CRP, swollen joint based on 28 joints and higher PASI compared with patients treated with GLM. Treatment with IFX, GLM and UST was associated with significant improvements in all disease parameters over time (p<0.001) from baseline up to 84, 84 and 40 months, respectively. AEs were reported for 74.8%, 69.8% and 52.9% (138, 114 and 115 events/100 patient-years (PYs)) covering 325, 567 and 87 years of exposure for IFX-treated, GLM-treated and UST-treated patients, respectively. Severe AEs were reported in 19.8%, 8.5% and 5.7% (8.8, 7.2 and 8.0 events/100 PYs) in IFX-treated, GLM-treated and UST-treated patients, respectively. The proportion of patients who discontinued treatment were 63.1%, 50.9% and 50.0%, respectively. Conclusions IFX, GLM and UST treatment significantly reduced disease activity and improved functionality in patients with PsA followed by routine clinical practice and had a safety profile similar to that previously reported in the literature. Trial registration number NCT00741793 ." @default.
• W3048606852 created "2020-08-18" @default.
• W3048606852 creator A5009712221 @default.
• W3048606852 creator A5033121652 @default.
• W3048606852 creator A5053065178 @default.
• W3048606852 creator A5056879469 @default.
• W3048606852 creator A5065964920 @default.
• W3048606852 creator A5066821940 @default.
• W3048606852 creator A5069216403 @default.
• W3048606852 creator A5083952133 @default.
• W3048606852 date "2020-08-01" @default.
• W3048606852 modified "2023-09-30" @default.
• W3048606852 title "Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry" @default.
• W3048606852 cites W1582428366 @default.
• W3048606852 cites W1835490086 @default.
• W3048606852 cites W2006359292 @default.
• W3048606852 cites W2059631907 @default.
• W3048606852 cites W2077202836 @default.
• W3048606852 cites W2094328816 @default.
• W3048606852 cites W2097973532 @default.
• W3048606852 cites W2102350540 @default.
• W3048606852 cites W2102987799 @default.
• W3048606852 cites W2108984264 @default.
• W3048606852 cites W2113669300 @default.
• W3048606852 cites W2119684753 @default.
• W3048606852 cites W2137101132 @default.
• W3048606852 cites W2148772912 @default.
• W3048606852 cites W2159628003 @default.
• W3048606852 cites W2159697181 @default.
• W3048606852 cites W2167905575 @default.
• W3048606852 cites W2170800858 @default.
• W3048606852 cites W2214981256 @default.
• W3048606852 cites W2247898976 @default.
• W3048606852 cites W2271197668 @default.
• W3048606852 cites W2333518989 @default.
• W3048606852 cites W2336136362 @default.
• W3048606852 cites W2541643654 @default.
• W3048606852 cites W2753791039 @default.
• W3048606852 cites W2808257985 @default.
• W3048606852 cites W2886829994 @default.
• W3048606852 cites W2889613994 @default.
• W3048606852 cites W2890513523 @default.
• W3048606852 cites W2897148118 @default.
• W3048606852 cites W2897926336 @default.
• W3048606852 cites W2903378072 @default.
• W3048606852 cites W2905301730 @default.
• W3048606852 cites W2913875901 @default.
• W3048606852 cites W2920982836 @default.
• W3048606852 cites W2940683833 @default.
• W3048606852 cites W3023200640 @default.
• W3048606852 doi "https://doi.org/10.1136/bmjopen-2019-036245" @default.
• W3048606852 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7430557" @default.
• W3048606852 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32792436" @default.
• W3048606852 hasPublicationYear "2020" @default.
• W3048606852 type Work @default.
• W3048606852 sameAs 3048606852 @default.
• W3048606852 citedByCount "2" @default.
• W3048606852 countsByYear W30486068522020 @default.
• W3048606852 countsByYear W30486068522023 @default.
• W3048606852 crossrefType "journal-article" @default.
• W3048606852 hasAuthorship W3048606852A5009712221 @default.
• W3048606852 hasAuthorship W3048606852A5033121652 @default.
• W3048606852 hasAuthorship W3048606852A5053065178 @default.
• W3048606852 hasAuthorship W3048606852A5056879469 @default.
• W3048606852 hasAuthorship W3048606852A5065964920 @default.
• W3048606852 hasAuthorship W3048606852A5066821940 @default.
• W3048606852 hasAuthorship W3048606852A5069216403 @default.
• W3048606852 hasAuthorship W3048606852A5083952133 @default.
• W3048606852 hasBestOaLocation W30486068521 @default.
• W3048606852 hasConcept C126322002 @default.
• W3048606852 hasConcept C141071460 @default.
• W3048606852 hasConcept C16005928 @default.
• W3048606852 hasConcept C1862650 @default.
• W3048606852 hasConcept C2776260265 @default.
• W3048606852 hasConcept C2777011040 @default.
• W3048606852 hasConcept C2777077863 @default.
• W3048606852 hasConcept C2777138892 @default.
• W3048606852 hasConcept C2778019847 @default.
• W3048606852 hasConcept C2778143017 @default.
• W3048606852 hasConcept C2778975655 @default.
• W3048606852 hasConcept C2779134260 @default.
• W3048606852 hasConcept C2780131103 @default.
• W3048606852 hasConcept C2780564577 @default.
• W3048606852 hasConcept C2781290027 @default.
• W3048606852 hasConcept C71924100 @default.
• W3048606852 hasConceptScore W3048606852C126322002 @default.
• W3048606852 hasConceptScore W3048606852C141071460 @default.
• W3048606852 hasConceptScore W3048606852C16005928 @default.
• W3048606852 hasConceptScore W3048606852C1862650 @default.
• W3048606852 hasConceptScore W3048606852C2776260265 @default.
• W3048606852 hasConceptScore W3048606852C2777011040 @default.
• W3048606852 hasConceptScore W3048606852C2777077863 @default.
• W3048606852 hasConceptScore W3048606852C2777138892 @default.
• W3048606852 hasConceptScore W3048606852C2778019847 @default.
• W3048606852 hasConceptScore W3048606852C2778143017 @default.
• W3048606852 hasConceptScore W3048606852C2778975655 @default.
• W3048606852 hasConceptScore W3048606852C2779134260 @default.
• W3048606852 hasConceptScore W3048606852C2780131103 @default.

• next